nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—SLC6A2—locus ceruleus—endogenous depression	0.112	0.19	CbGeAlD
Lisdexamfetamine—SLC6A2—sympathetic nervous system—endogenous depression	0.0886	0.15	CbGeAlD
Lisdexamfetamine—SLC6A2—autonomic nervous system—endogenous depression	0.0596	0.101	CbGeAlD
Lisdexamfetamine—SLC6A3—Clearance of dopamine—COMT—endogenous depression	0.0489	0.135	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Clearance of dopamine—MAOA—endogenous depression	0.0486	0.134	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—brainstem—endogenous depression	0.0236	0.0399	CbGeAlD
Lisdexamfetamine—SLC18A2—forebrain—endogenous depression	0.0228	0.0385	CbGeAlD
Lisdexamfetamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—COMT—endogenous depression	0.0223	0.0614	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—MAOA—endogenous depression	0.0222	0.061	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Norepinephrine Neurotransmitter Release Cycle—MAOA—endogenous depression	0.0194	0.0535	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—brainstem—endogenous depression	0.0178	0.0302	CbGeAlD
Lisdexamfetamine—SLC6A3—forebrain—endogenous depression	0.0172	0.0291	CbGeAlD
Lisdexamfetamine—SLC18A2—adrenal gland—endogenous depression	0.0152	0.0258	CbGeAlD
Lisdexamfetamine—SLC18A2—midbrain—endogenous depression	0.015	0.0254	CbGeAlD
Lisdexamfetamine—SLC18A2—thyroid gland—endogenous depression	0.0147	0.0249	CbGeAlD
Lisdexamfetamine—SLC6A2—brainstem—endogenous depression	0.0144	0.0243	CbGeAlD
Lisdexamfetamine—SLC6A2—forebrain—endogenous depression	0.0139	0.0235	CbGeAlD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TPH2—endogenous depression	0.0137	0.0378	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—endocrine gland—endogenous depression	0.0132	0.0223	CbGeAlD
Lisdexamfetamine—ADRA1B—nervous system—endogenous depression	0.0125	0.0211	CbGeAlD
Lisdexamfetamine—SLC18A2—nervous system—endogenous depression	0.0124	0.0209	CbGeAlD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TPH2—endogenous depression	0.0122	0.0335	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—central nervous system—endogenous depression	0.012	0.0203	CbGeAlD
Lisdexamfetamine—SLC18A2—central nervous system—endogenous depression	0.0119	0.0201	CbGeAlD
Lisdexamfetamine—SLC18A2—cerebellum—endogenous depression	0.0116	0.0197	CbGeAlD
Lisdexamfetamine—SLC6A3—midbrain—endogenous depression	0.0114	0.0192	CbGeAlD
Lisdexamfetamine—SLC18A2—Synaptic Vesicle Pathway—SLC6A4—endogenous depression	0.0112	0.0309	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—SLC6A4—endogenous depression	0.011	0.0302	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neurotransmitter Release Cycle—MAOA—endogenous depression	0.00987	0.0272	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—SLC6A4—endogenous depression	0.00972	0.0267	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—brain—endogenous depression	0.00953	0.0161	CbGeAlD
Lisdexamfetamine—SLC18A2—brain—endogenous depression	0.00944	0.016	CbGeAlD
Lisdexamfetamine—SLC6A3—nervous system—endogenous depression	0.00934	0.0158	CbGeAlD
Lisdexamfetamine—SLC6A2—adrenal gland—endogenous depression	0.00929	0.0157	CbGeAlD
Lisdexamfetamine—SLC6A3—central nervous system—endogenous depression	0.009	0.0152	CbGeAlD
Lisdexamfetamine—SLC6A3—cerebellum—endogenous depression	0.00879	0.0149	CbGeAlD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—HTR1A—endogenous depression	0.00855	0.0235	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—HTR2C—endogenous depression	0.00826	0.0227	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—endocrine gland—endogenous depression	0.00805	0.0136	CbGeAlD
Lisdexamfetamine—Selegiline—MAOA—endogenous depression	0.00767	0.168	CrCbGaD
Lisdexamfetamine—SLC6A2—nervous system—endogenous depression	0.00754	0.0128	CbGeAlD
Lisdexamfetamine—SLC6A2—central nervous system—endogenous depression	0.00726	0.0123	CbGeAlD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—HTR7—endogenous depression	0.00723	0.0199	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—HTR1A—endogenous depression	0.00719	0.0198	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—brain—endogenous depression	0.00714	0.0121	CbGeAlD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—HTR2C—endogenous depression	0.00694	0.0191	CbGpPWpGaD
Lisdexamfetamine—Phenelzine—MAOA—endogenous depression	0.00676	0.148	CrCbGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—HTR7—endogenous depression	0.00608	0.0167	CbGpPWpGaD
Lisdexamfetamine—Methamphetamine—MAOA—endogenous depression	0.0059	0.129	CrCbGaD
Lisdexamfetamine—SLC6A2—brain—endogenous depression	0.00576	0.00975	CbGeAlD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—HTR2A—endogenous depression	0.00507	0.0139	CbGpPWpGaD
Lisdexamfetamine—Labetalol—CYP2D6—endogenous depression	0.00478	0.105	CrCbGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—CACNB2—endogenous depression	0.00471	0.013	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—HTR2A—endogenous depression	0.00426	0.0117	CbGpPWpGaD
Lisdexamfetamine—Amphetamine—SLC6A4—endogenous depression	0.00411	0.09	CrCbGaD
Lisdexamfetamine—Methamphetamine—SLC6A4—endogenous depression	0.00381	0.0834	CrCbGaD
Lisdexamfetamine—SLC18A2—Neuronal System—CACNB2—endogenous depression	0.00361	0.00993	CbGpPWpGaD
Lisdexamfetamine—Dextroamphetamine—CYP2D6—endogenous depression	0.00358	0.0785	CrCbGaD
Lisdexamfetamine—Selegiline—CYP2D6—endogenous depression	0.00347	0.0761	CrCbGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC6A4—endogenous depression	0.00326	0.00896	CbGpPWpGaD
Lisdexamfetamine—Amphetamine—CYP2D6—endogenous depression	0.00289	0.0633	CrCbGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC6A4—endogenous depression	0.00289	0.00794	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—COMT—endogenous depression	0.00285	0.00785	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—MAOA—endogenous depression	0.00283	0.00779	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—CACNA1C—endogenous depression	0.00283	0.00779	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—CACNB2—endogenous depression	0.00281	0.00772	CbGpPWpGaD
Lisdexamfetamine—Methamphetamine—CYP2D6—endogenous depression	0.00268	0.0586	CrCbGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—OXT—endogenous depression	0.00222	0.0061	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—COMT—endogenous depression	0.00219	0.00601	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—MAOA—endogenous depression	0.00217	0.00597	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—CACNB2—endogenous depression	0.00215	0.00592	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—HTR2C—endogenous depression	0.00206	0.00567	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—OXT—endogenous depression	0.00198	0.00546	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2C—endogenous depression	0.00184	0.00507	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—COMT—endogenous depression	0.0017	0.00468	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—MAOA—endogenous depression	0.00169	0.00465	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR1A—endogenous depression	0.00165	0.00454	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2C—endogenous depression	0.00159	0.00439	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—OXT—endogenous depression	0.00147	0.00404	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR1A—endogenous depression	0.00141	0.00389	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR7—endogenous depression	0.0014	0.00384	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2C—endogenous depression	0.00137	0.00376	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ADM—endogenous depression	0.00133	0.00367	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—COMT—endogenous depression	0.0013	0.00358	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—MAOA—endogenous depression	0.00129	0.00356	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—HTR2A—endogenous depression	0.00126	0.00348	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR7—endogenous depression	0.0012	0.00329	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—endogenous depression	0.00113	0.00311	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CRH—endogenous depression	0.00112	0.00308	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—OXT—endogenous depression	0.00112	0.00308	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR1A—endogenous depression	0.00108	0.00296	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR2C—endogenous depression	0.00104	0.00286	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—endogenous depression	0.000978	0.00269	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR7—endogenous depression	0.000911	0.00251	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—endogenous depression	0.000838	0.00231	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADM—endogenous depression	0.000754	0.00208	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADM—endogenous depression	0.000685	0.00188	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—endogenous depression	0.000669	0.00184	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR2A—endogenous depression	0.000638	0.00176	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—OXT—endogenous depression	0.000632	0.00174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CRH—endogenous depression	0.000632	0.00174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR1A—endogenous depression	0.000609	0.00167	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR2C—endogenous depression	0.000588	0.00162	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—OXT—endogenous depression	0.000574	0.00158	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CRH—endogenous depression	0.000574	0.00158	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR1A—endogenous depression	0.000553	0.00152	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR2C—endogenous depression	0.000534	0.00147	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR7—endogenous depression	0.000515	0.00142	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—POMC—endogenous depression	0.00051	0.0014	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR7—endogenous depression	0.000467	0.00129	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—WASF2—endogenous depression	0.000442	0.00122	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—WASF1—endogenous depression	0.000424	0.00117	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADM—endogenous depression	0.000405	0.00111	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR2A—endogenous depression	0.000361	0.000992	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—OXT—endogenous depression	0.000339	0.000933	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CRH—endogenous depression	0.000339	0.000933	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR2A—endogenous depression	0.000327	0.000901	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR1A—endogenous depression	0.000326	0.000898	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR2C—endogenous depression	0.000315	0.000868	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—POMC—endogenous depression	0.000288	0.000792	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR7—endogenous depression	0.000276	0.00076	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—POMC—endogenous depression	0.000261	0.000719	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR2A—endogenous depression	0.000193	0.000532	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—POMC—endogenous depression	0.000154	0.000425	CbGpPWpGaD
